La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
ResMed Bilan de santé
Santé financière contrôle des critères 6/6
ResMed has a total shareholder equity of $4.9B and total debt of $707.2M, which brings its debt-to-equity ratio to 14.5%. Its total assets and total liabilities are $6.9B and $2.0B respectively. ResMed's EBIT is $1.4B making its interest coverage ratio 30.3. It has cash and short-term investments of $250.4M.
Informations clés
14.5%
Ratio d'endettement
US$707.21m
Dette
| Ratio de couverture des intérêts | 30.3x |
| Argent liquide | US$250.39m |
| Fonds propres | US$4.86b |
| Total du passif | US$2.01b |
| Total des actifs | US$6.87b |
Mises à jour récentes de la santé financière
Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?
Jul 29
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt
May 26ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Feb 06Recent updates
ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53
Aug 05Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?
Jul 29Returns On Capital Are A Standout For ResMed (NYSE:RMD)
Jul 15ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating
Jul 03An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued
Jul 02ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 30ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear
Apr 18With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case
Mar 22Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future
Mar 10An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued
Feb 12Why ResMed Is One Of My Top Picks In 2024
Jan 22A First Look At ResMed
Jan 09ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk
Dec 20Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital
Dec 06Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now
Nov 10Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?
Nov 01ResMed: Weight-Loss Drug Worries Provide Buying Opportunity
Oct 28ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity
Sep 12ResMed Has Become A Steal (Rating Upgrade)
Aug 10ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 07ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger
Jul 30Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Jul 16Compound Your Wealth With ResMed
Jul 04A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)
Jul 02We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt
May 26ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital
Apr 24Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors
Apr 09A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)
Mar 26ResMed goes ex dividend tomorrow
Feb 07ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Feb 06Analyse de la situation financière
Passif à court terme: RMD's short term assets ($2.4B) exceed its short term liabilities ($910.7M).
Passif à long terme: RMD's short term assets ($2.4B) exceed its long term liabilities ($1.1B).
Historique et analyse du ratio d'endettement
Niveau d'endettement: RMD's net debt to equity ratio (9.4%) is considered satisfactory.
Réduire la dette: RMD's debt to equity ratio has reduced from 61.3% to 14.5% over the past 5 years.
Couverture de la dette: RMD's debt is well covered by operating cash flow (198.1%).
Couverture des intérêts: RMD's interest payments on its debt are well covered by EBIT (30.3x coverage).